DEFTA Partners

What DEFTA Partners does

DEFTA Partners is a privately held venture capital and private investment firm founded in the 1980s by George Hara and headquartered in San Francisco, with regional offices in Tokyo (Yokohama) and Hong Kong. The firm identifies, nurtures, and funds early-stage technology companies, focusing on three pillars: healthcare (advanced therapeutics, health ICT, and enabling technologies aimed at enabling healthy longevity), ICT under its "pervasive ubiquitous communications" (PUC) thesis (encompassing embedded devices, digital TV, and online security), and global investments that support portfolio companies scaling across North America, Europe, Asia, and the Middle East. DEFTA has invested in more than 100 companies since the 1980s across the U.S., U.K., Israel, Bangladesh, and Japan, with notable historical investments including the first gene therapy company (Viagene), the first antisense therapy company (Isis Pharmaceuticals), the first bioinformatics company (Arris Pharmaceuticals), and Fortinet (which went public in 2009).

The firm operates through DEFTA Capital, DEFTA Corporation, and DEFTA Healthcare Technologies, and maintains a strategic joint venture with BRAC (the world's largest NGO) to operate bracNet, an internet service provider in Bangladesh. Revenue is generated through equity investments in early-stage technology companies, with returns realized via exits such as IPOs (e.g., Fortinet, 2009) and M&A; pricing and investment terms are individually negotiated with portfolio companies and are not publicly disclosed. The firm does not develop or sell products itself; its "technology" is the proprietary PUC investment thesis and the global network that supports portfolio internationalization. The leadership team, anchored by Group Chairman & CEO George Hara, leverages Hara's senior advisory roles to Japan's government (Senior Advisor to the Minister of Finance, 2005-2009; Deputy Chairman of the Expert Panel on Economic and Fiscal Policy; Prime Minister's Special Commissioner on the Government Tax Panel) to source cross-border deal flow, particularly between the U.S. and Japan.

Name

DEFTA Partners

Legal name

DEFTA Partners

Website

https://deftapartners.com

Company type

Private

Founded year

1980

Operating status

Operating

Headcount range

11–50 employees

Short description

DEFTA Partners is a privately held venture capital firm founded in the 1980s by George Hara, headquartered in San Francisco with offices in Tokyo and Hong Kong. It funds early-stage technology companies in healthcare (advanced therapeutics, health ICT) and ICT (pervasive ubiquitous communications) across 100+ investments globally.

Ownership category

akta.pro rank

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

1. Venture Capital Returns: DEFTA Partners generates returns through equity investments in early-stage technology companies. The firm identifies and funds innovative companies with the goal of leading them to global success, with successful exits including first gene therapy company Viagene, first antisense therapy company Isis Pharmaceuticals, and first bioinformatics company Arris Pharmaceuticals.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

DEFTA Partners is a venture capital firm that identifies, nurtures, and funds early-stage technology companies primarily in Healthcare (advanced therapeutics, health ICT, and enabling technologies) and ICT (pervasive ubiquitous communications model covering embedded devices, digital TV, and online security). The firm takes equity positions and provides hands-on global expertise to help portfolio companies scale internationally across North America, Europe, Asia, and the Middle East.

Product overview

DEFTA Partners is a venture capital firm, not a product company. The company identifies, nurtures, and funds early-stage technology companies. Their investment focus spans three main areas: Healthcare (advanced therapeutics, health ICT, and enabling technologies), ICT (pervasive ubiquitous communications model encompassing embedded devices, digital TV, and online security), and Global investments (with portfolio companies across North America, Europe, Asia, and the Middle East). The company has invested in more than 100 companies since the 1980s, with offices in San Francisco, Tokyo, and Hong Kong.

Differentiator

Problem solved

Functional benefit

Products and services

• Seed and Early-Stage Equity Investment

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• BRACcoreStrategic or Co-development PartnerDEFTA Partners works with BRAC, the world's largest NGO, in establishing and operating bracNet, an internet service provider in Bangladesh. This partnership demonstrates DEFTA's commitment to sustainable growth in developing markets and represents a core strategic alliance for expanding connectivity infrastructure.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• ARCH Venture Partners: ARCH Venture Partners is a long-tenured early-stage venture capital firm that invests in life sciences, physical sciences, and information technology companies, often at company formation or seed stage. Directly comparable to DEFTA in stage focus (seed/first-round) and sector mix (healthcare + deep tech), with a similarly long track record of identifying category-defining science and technology companies.
• DCVC (Data Collective): DCVC is an early-stage venture capital firm backing deep-tech and science-driven companies at the seed and Series A stages. Comparable to DEFTA's focus on pervasive ubiquitous communications, embedded devices, and advanced therapeutics with similarly conviction-driven early-stage capital deployment.
• Founders Fund: Founders Fund is a San Francisco-based venture capital firm that invests in early-stage technology companies across a range of frontier technology areas. Comparable to DEFTA in early-stage technology focus, San Francisco base, and orientation toward deep-technology and science-driven investments.
• Lux Capital: Lux Capital is an early-stage venture firm investing in emerging science and technology ventures at the intersection of science, health, and technology. Closely comparable to DEFTA's focus on advanced therapeutics, health ICT, and pervasive ubiquitous communications, with similar seed-to-Series A entry strategy and emerging-tech orientation.
• Draper Associates: Draper Associates is an early-stage venture capital firm focused on seed and Series A investments in technology companies with a global orientation. Directly comparable to DEFTA in stage (seed/first-round), sector (technology), and willingness to back emerging-market and cross-border technology plays.
• Khosla Ventures: Khosla Ventures is an early-stage venture firm investing across technology, sustainability, and healthcare with a high tolerance for risk and a willingness to fund unconventional ideas. Directly comparable to DEFTA in seed/first-round entry, healthcare-technology crossover focus, and pattern of identifying contrarian, first-in-category opportunities.

Broad incumbents

• Andreessen Horowitz: Andreessen Horowitz (a16z) is a broad-based venture capital firm investing across stages and sectors with significant activity in early-stage technology and bio/healthcare. Comparable as an incumbent in the same early-stage technology and healthcare investing arena that DEFTA occupies, though much larger and more diversified across stages and geographies.
• Bessemer Venture Partners: Bessemer Venture Partners is a long-tenured venture capital firm with a multi-stage approach and notable presence in early-stage technology and healthcare. Comparable to DEFTA's early-stage technology and healthcare focus, though BVP operates at much greater scale across more stages and geographies.
• Kleiner Perkins: Kleiner Perkins is a long-established Silicon Valley venture capital firm with historic strength in early-stage technology and healthcare investing. Comparable to DEFTA as a long-tenured early-stage tech and healthcare investor, though Kleiner operates at significantly greater scale and brand visibility.
• New Enterprise Associates (NEA): New Enterprise Associates is a large, multi-stage venture capital firm investing across technology and healthcare. Comparable to DEFTA in its dual focus on technology and healthcare, though NEA operates at significantly larger scale with a broader stage range and more institutional LP base.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/defta-partners

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments35 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DEFTA Partners